3788-16-7

Usage

Uses

Used in Pharmaceutical Industry:
Cimemoxin is used as a therapeutic agent for the treatment of Alzheimer's disease due to its ability to inhibit the formation of amyloid plaques, which are associated with the progression of the disease.
Used in Neuroprotection:
Cimemoxin is used as a neuroprotective agent for its antioxidant properties, which help protect and repair brain cells damaged by oxidative stress, potentially slowing down the progression of neurodegenerative disorders.
Used in Cognitive Function Improvement:
Cimemoxin is used as a cognitive enhancer to improve cognitive function and memory, as demonstrated in animal studies, offering hope for the development of treatments that can enhance brain health and function in patients with Alzheimer's disease and related conditions.

InChI:InChI=1/C7H16N2/c8-9-6-7-4-2-1-3-5-7/h7,9H,1-6,8H2

Upstream product

• 3637-60-3 N-Acetyl-N'-hexahydrobenzylhydrazin 
• 149267-56-1 N-1-(tert-butoxycarbonyl)-N-2-(cyclohexylmethyl)hydrazine 
• 100-50-5 3-Cyclohexene-1-carboxaldehyde 
• 3637-59-0 1,2,3,6-Tetrahydro-benzaldehyd-acethydrazon 
• 654058-77-2 N-((1Z)-1-aza-2-cyclohexylvinyl)(tert-butoxy)carboxamide 
• 2043-61-0 cyclohexanecarbaldehyde 

Downstream Products

• 17697-23-3 N,N'-Dibenzoyl-N-cyclohexylmethyl-hydrazin 
• 654058-81-8 methyl 1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazole-3-carboxylate 
• 1561965-95-4 ethyl 5-(4-(N-(tert-butyl)sulfamoyl)-2,3-dichlorophenyl)-1-(cyclohexylmethyl)-1H-pyrazole-3-carboxylate 
• 957507-55-0 C₁₁H₁₉N₃ 
• 654058-53-4 3-[1-cyclohexylmethyl-5-(4-methanesulfonyl-phenyl)-1H-pyrazol-3-yl]-propan-1-ol 
• 654058-52-3 1-(3-((1E)-3-hydroxyprop-1-enyl)1-(cyclohexylmethyl)pyrazol-5-yl)-4-(methylsulfonyl)benzene 
• 654058-95-4 methyl (2E)-3-[1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazol-3-yl]prop-2-enoate 
• 654058-98-7 3-(1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazol-3-yl)propan-1-ol 
• 654058-96-5 (2E)-3-(1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazol-3-yl)prop-2-en-ol-1 
• 654058-48-7 [1-cyclohexylmethyl-5-(4-methanesulfonyl-phenyl)-1H-pyrazol-3-yl]-methanol 
• 654058-83-0 (1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazol-3-yl)methanol 
• 654058-94-3 1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazole-3-carbaldehyde 

Relevant academic research and scientific papers

Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators

The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.

Synthesis and Selective Cyclooxygenase-2 Inhibitory Activity of a Series of Novel, Nitric Oxide Donor-Containing Pyrazoles

The synthesis of a series of novel pyrazoles containing a nitrate (ONO 2) moiety as a nitric oxide (NO)-donor functionality is reported. Their COX-1 and COX-2 inhibitory activities in human whole blood are profiled. Our data demonstrate that py